Dr. Reddy's Laboratories/$RDY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Dr. Reddy's Laboratories

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Ticker

$RDY
Sector

Primary listing

NYSE

Employees

27,811

Headquarters

Hyderabad, India

RDY Metrics

BasicAdvanced
$12B
18.29
$0.77
0.32
$0.07
0.51%

What the Analysts think about RDY

Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.

Bulls say / Bears say

Dr. Reddy’s European revenue more than doubled in Q2 FY25, driven by strong demand for the Nicotine Replacement Therapy portfolio acquired from Haleon, underscoring successful diversification beyond generics (Reuters)
Dr. Reddy’s plans to launch generic Wegovy in 87 countries starting next year, positioning the company to capture share in the rapidly growing obesity drug market projected to reach $150 billion by the early 2030s (Reuters)
As of June 2025, Dr. Reddy’s had 73 pending ANDA filings with the U.S. FDA, including 43 Paragraph IVs and 22 with first-to-file potential, ensuring a robust pipeline for future generics launches in North America (Business Standard)
Revenue in North America fell 11.3% in Q2 FY25 due to price erosion in key products like Lenalidomide, revealing significant vulnerability in Dr. Reddy’s largest market (Reuters)
Dr. Reddy’s narrow profit miss in Q2 FY25, with net earnings of ₹14.18 billion versus ₹14.94 billion estimated, underscores margin pressure from intensifying generic competition (Reuters)
The upcoming patent expiries for semaglutide will trigger intense competition in the obesity drug segment from peers such as Biocon, Cipla, and Lupin, potentially compressing Dr. Reddy’s pricing power and margins (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

RDY Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RDY Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RDY

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs